Literature DB >> 20148838

A dramatic response to a single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of von Zumbusch associated with a neutrophilic cholangitis.

Nisha Suyien Chandran1, Wei-Sheng Chong.   

Abstract

Generalized pustular psoriasis of von Zumbusch is an unstable, inflammatory form of psoriasis, with the hallmark of neutrophil infiltration in cutaneous as well as extracutaneous lesions. It is often recalcitrant, making treatment difficult. Tumour necrosis factor-alpha antagonists including infliximab have been used with success in treating recalcitrant cases. We report a case of a 48-year-old Chinese female patient with a long-standing history of poorly controlled generalized pustular psoriasis which was resistant to multiple therapies. During a severe flare, a single dose of infliximab resulted in rapid clearing of cutaneous lesions, together with resolution of liver function abnormalities that are likely secondary to neutrophilic cholangitis. Subsequent maintenance therapy with acitretin allowed remission of pustular disease for 7 months. This demonstrates the efficacy of single-dose infliximab for both cutaneous lesions and systemic hepatic involvement in generalized pustular psoriasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20148838     DOI: 10.1111/j.1440-0960.2009.00588.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  2 in total

1.  A mysterious abdominal pain during active psoriasis.

Authors:  Valentina Della Valle; Marco Maggioni; Carlo Carrera; Angelo Cattaneo; Angelo Valerio Marzano; Giovanni Damiani
Journal:  Intern Emerg Med       Date:  2017-10-30       Impact factor: 3.397

2.  Two cases of generalized pustular psoriasis: successful treatment with infliximab.

Authors:  Hoon-Soo Kim; Hyang-Suk You; Hyun-Ho Cho; Won Jeong Kim; Je-Ho Mun; Margaret Song; Hyun-Chang Ko; Moon-Bum Kim; Byung-Soo Kim
Journal:  Ann Dermatol       Date:  2014-11-26       Impact factor: 1.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.